


Tissue Expansion / Implant Reconstruction with Repriza[®] Acellular Dermal Matrix: Recent Clinical Experience

Background: Expander/Implant breast reconstruction with human acellular dermal matrix placed at the time of mastectomy has become a standard and popular technique. The purpose of this study was to review the clinical results of a new acellular dermal matrix called Repriza[®]. This product comes packaged sterile and is provided prehydrated.

Methods: A retrospective analysis of data on 139 breasts in 75 patients that underwent immediate tissue expander breast reconstruction. All mastectomies were performed by the same general surgeon and all breast reconstructions were performed by the same plastic surgeon utilizing the Repriza[®] Acellular Dermal Matrix. A secondary stage reconstruction was performed with placement of a gel implant between 12 to 16 weeks after placement of the expander.

Results: 75 consecutive patients (139 breasts) underwent immediate breast reconstruction with tissue expansion and (Repriza) an acellular dermal construct. Major complication rate was 3.6% overall (5 complications). Infection with expander removal accounted for 3 (2.2%) and hematomas for 2 (1.4%). Follow up time period averaged 18 months (Range, 3 to 34). Breast reconstructions subjected to radiation were excluded from the analysis.

Conclusions: Based on the investigators experience and the published data regarding Alloderm[®], this study indicates less major complication rates with the new product Repriza[®] Acellular Dermal Matrix. To be presented as an abstract for future publication.



Complete integration of the Repriza[®] acellular dermal matrix at time of 2nd stage with excellent thickness and vascularization



Richard B. Williams, M.D., F.A.C.S.

rwilliams@tpsg.net

Tissue Expansion with Repriza Acellular Dermal Matrix	
Number of Patients	75
Number of reconstructed Breasts	139
Unilateral reconstructions	11 (15%)
Bilateral reconstructions	64 (85%)
Initial Expander Fill Volume	200 to 340cc
Duration of drains in Breast (days)	10 to 14
MAJOR COMPLICATIONS	
Infection	3 (2.2%)
Hematoma	2 (1.4%)
Capsular Contracture	0
TOTAL Major complications	5 (3.6%)
Seroma after Drain removal (resolved with aspiration)	4 (2.9%)
TOTAL ALL Complications	9 (6.5%)
Follow UP Time: (Months)	
Minimum	3
Maximum	34
Mean	18



SPECIALTY SURGICAL PRODUCTS, INC.

888-878-0811